BN
|
HealthAI Desk•2 views

Eli Lilly's Foundayo Gains FDA Approval for Obesity

The U.S. FDA has approved Eli Lilly's Foundayo, an oral GLP-1 pill for obesity treatment. The drug will be available through LillyDirect starting April 6, with broader retail rollout planned. Foundayo offers advantages over Novo Nordisk's Wegovy, including no dietary restrictions. Clinical trials showed Foundayo's superiority in weight loss for diabetes patients. Lilly's stock rose 5% on the news, and sales are projected to reach $1.55 billion in 2025. The company is also pursuing regulatory approval for Foundayo as a diabetes medication.

Ad slot
Eli Lilly's Foundayo Gains FDA Approval for Obesity

Eli Lilly has received FDA approval for Foundayo, a once-daily oral GLP-1 medication for obesity, with immediate prescription availability through its LillyDirect platform.

Approval and Drug Details

  • The FDA approved Foundayo on April 2, 2025.
  • Active ingredient: orforglipron.
  • It is a once-daily pill for chronic weight management.

Launch and Availability

  • Prescriptions accepted immediately via LillyDirect.
  • Shipping begins April 6, 2025.
  • Expansion to retail pharmacies and telehealth providers to follow.
  • Lilly prepared a stockpile to meet anticipated demand.

Competitive Comparison

  • Competes directly with Novo Nordisk's oral Wegovy.
  • Foundayo has no restrictions on food, water, or time of intake.
  • Wegovy must be taken on an empty stomach in the morning.
  • In a head-to-head study, Foundayo showed better weight loss benefits in diabetes patients compared to oral Wegovy.

Market Impact

  • Eli Lilly's stock increased approximately 5% following the announcement.
  • Analysts forecast 2025 sales of $1.55 billion, rising to $14.8 billion by 2030 (FactSet).
  • Lilly is also seeking FDA approval for Foundayo in diabetes treatment.
Ad slot
Ad slot